1. Home
  2. DKL vs ARQT Comparison

DKL vs ARQT Comparison

Compare DKL & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DKL
  • ARQT
  • Stock Information
  • Founded
  • DKL 2012
  • ARQT 2016
  • Country
  • DKL United States
  • ARQT United States
  • Employees
  • DKL N/A
  • ARQT 342
  • Industry
  • DKL Natural Gas Distribution
  • ARQT Biotechnology: Pharmaceutical Preparations
  • Sector
  • DKL Energy
  • ARQT Health Care
  • Exchange
  • DKL Nasdaq
  • ARQT Nasdaq
  • Market Cap
  • DKL 2.1B
  • ARQT 1.7B
  • IPO Year
  • DKL N/A
  • ARQT 2020
  • Fundamental
  • Price
  • DKL $38.33
  • ARQT $13.52
  • Analyst Decision
  • DKL Buy
  • ARQT Strong Buy
  • Analyst Count
  • DKL 4
  • ARQT 6
  • Target Price
  • DKL $44.25
  • ARQT $18.80
  • AVG Volume (30 Days)
  • DKL 211.0K
  • ARQT 2.1M
  • Earning Date
  • DKL 05-07-2025
  • ARQT 05-06-2025
  • Dividend Yield
  • DKL 11.50%
  • ARQT N/A
  • EPS Growth
  • DKL 7.97
  • ARQT N/A
  • EPS
  • DKL 2.98
  • ARQT N/A
  • Revenue
  • DKL $938,491,000.00
  • ARQT $212,819,000.00
  • Revenue This Year
  • DKL $15.88
  • ARQT $57.99
  • Revenue Next Year
  • DKL $0.37
  • ARQT $41.24
  • P/E Ratio
  • DKL $12.85
  • ARQT N/A
  • Revenue Growth
  • DKL N/A
  • ARQT 100.03
  • 52 Week Low
  • DKL $34.59
  • ARQT $6.99
  • 52 Week High
  • DKL $45.71
  • ARQT $17.75
  • Technical
  • Relative Strength Index (RSI)
  • DKL 45.38
  • ARQT 42.59
  • Support Level
  • DKL $38.25
  • ARQT $12.42
  • Resistance Level
  • DKL $39.65
  • ARQT $15.67
  • Average True Range (ATR)
  • DKL 1.18
  • ARQT 0.87
  • MACD
  • DKL 0.19
  • ARQT -0.03
  • Stochastic Oscillator
  • DKL 57.33
  • ARQT 33.69

About DKL Delek Logistics Partners L.P. Common Units representing Limited Partner Interests

Delek Logistics Partners LP owns and operates logistics and marketing assets for crude oil and intermediate and refined products. The company's segment includes gathering and processing; wholesale marketing and terminalling; storage and transportation and investment in pipeline joint ventures. It generates maximum revenue from the wholesale marketing and terminalling segment, which provides marketing services for the refined products output of the Delek Holdings' refineries, engages in wholesale activity at its terminals and terminals owned by third parties, whereby it purchases light product for sale and exchange to third parties, and provides terminalling services at its refined products terminals to independent third parties and Delek Holdings.

About ARQT Arcutis Biotherapeutics Inc.

Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.

Share on Social Networks: